Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

No longer available 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
PSMA-11 × Clear all
NCT03181867 2026-04-22

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
360 enrolled
Genitourinary

Prostatic Neoplasms

NCT04825652 2023-01-13

177Lu-PSMA-617 Managed Access Program for mCRPC Patients

Advanced Accelerator Applications

No longer available
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡